Published in Cardiovasc Diagn Ther on December 01, 2014
[The subcutaneous cardioverter-defibrillator: When less is more]. Herzschrittmacherther Elektrophysiol (2015) 0.84
Clinical and electrocardiographic predictors of T wave oversensing in patients with subcutaneous ICD. J Arrhythm (2016) 0.77
Totally submuscular implantation of subcutaneous implantable cardioverter defibrillator: a safe and effective solution for obese or oversized patients. Clin Case Rep (2016) 0.75
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA (2003) 5.30
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J (2014) 3.91
End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol (2011) 3.21
Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation (2013) 3.14
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03
Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol (2011) 2.98
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm (2012) 2.65
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation (2010) 2.45
Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm (2005) 2.43
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J (2005) 2.28
Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol (2013) 2.28
Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm (2014) 2.06
The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol (2012) 1.93
Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation (2014) 1.93
Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm (2012) 1.91
Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation (2001) 1.69
The dilemma of ICD implant testing. Pacing Clin Electrophysiol (2007) 1.63
Shocks burden and increased mortality in implantable cardioverter-defibrillator patients. Heart Rhythm (2011) 1.61
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Heart Rhythm (2010) 1.54
Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation (2010) 1.52
Who should receive the subcutaneous implanted defibrillator?: The subcutaneous implantable cardioverter defibrillator (ICD) should be considered in all ICD patients who do not require pacing. Circ Arrhythm Electrophysiol (2013) 1.51
Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. Heart Rhythm (2013) 1.42
Prognostic impact of inappropriate defibrillator shocks in a population cohort. Heart (2013) 1.38
Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation (2006) 1.30
United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace (2013) 1.28
Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm (2013) 1.22
Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J (2012) 1.17
Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm (2014) 1.04
Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J (2008) 0.97
Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol (2014) 0.95
Evaluation of acute cardiac and chest wall damage after shocks with a subcutaneous implantable cardioverter defibrillator in Swine. Pacing Clin Electrophysiol (2013) 0.87
Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart (2013) 0.86
DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). Card Electrophysiol Rev (2003) 0.85
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. Eur Heart J (2013) 0.85
Rates of upgrade of ICD recipients to CRT in clinical practice and the potential impact of the more liberal use of CRT at initial implant. Pacing Clin Electrophysiol (2011) 0.84
Who should receive the subcutaneous implanted defibrillator?: Timing is not right to replace the transvenous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol (2013) 0.82
The subcutaneous implantable defibrillator: a new technology that raises an existential question for the implantable cardioverter-defibrillator. Circulation (2013) 0.81
Shock efficacy of the entirely subcutaneous defibrillator for termination of spontaneous ventricular fibrillation in Brugada syndrome. Heart Rhythm (2013) 0.80
Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation. J Am Coll Cardiol (1999) 0.79
Feasibility and efficacy of percutaneously delivered leadless cardiac pacing in an in vivo ovine model. J Cardiovasc Electrophysiol (2014) 0.78
[Antitachycardia pacing in patients with left ventricular dysfunction and hemodynamically unstable arrhythmias]. Rev Port Cardiol (1999) 0.77
Reducing shocks and improving outcomes with implantable defibrillators. JAMA (2013) 0.77
Early experience with the subcutaneous ICD. Curr Cardiol Rep (2014) 0.76